Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC

2016 ◽  
Vol 44 (4) ◽  
pp. 670-677 ◽  
Author(s):  
Christoph Berliner ◽  
Milena Tienken ◽  
Thorsten Frenzel ◽  
Yuske Kobayashi ◽  
Annabelle Helberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Detection Rate ◽  
Published Data ◽  
Biochemical Relapse ◽  
Pet Ct

scholarly journals Detection Rate of 18F-Fluorethylcholine-PET/CT in relation to PSA Value in PCA Patients Referred with Biochemical Relapse

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Mustafa Takesh ◽  
Khaldoun Odat Allh ◽  
Christian M. Zechmann
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Detection Rate ◽  
Local Relapse ◽  
Initial Therapy ◽  
Diagnostic Methods ◽  
Biochemical Relapse ◽  
Pet Ct ◽  
Significant Difference ◽  
Negative Findings

Attempts to predict the likelihood of positive morphological imaging related with PSA value in patients referred with biochemical recurrence were the focus of many studies. Using nuclear medicine modalities, numerous studies likewise had been performed for the same purpose, however mostly using C-11-labeled choline. For this purpose, we selected 193 prostate cancer patients from our database between 2006 and 2010. They had been referred to our department to undergo 18F-fluorethylcholine (FECH)-PET/CT due to biochemical recurrence after potentially curative procedures. As a result, in 84 out of 193 patients, 18F-FECH-PET demonstrated positive findings with an overall detection rate of 44%. Statistically, there was a significant difference in PSA values in positive findings vs. negative findings (p<0.001), and there was a linear correlation between the detection rate and PSA value (r = 0.91). Moreover, there was a relation between initial therapy and recurrence type. So, the local relapse was the most frequent recurrence (>70%) after radiation therapy alone. By contrast, patients after radical prostatectomy followed by salvage radiotherapy showed a low likelihood of local recurrence. In conclusion, PSA value was confirmed to have a determinant role in 18F-FECH-PET outcome. Moreover, there was a link between recurrence type and initial therapy, which—if prospectively confirmed—may play a guiding role in selecting the appropriate diagnostic methods.

scholarly journals Detection Rate and Clinical Impact of PET/CT with 18F-FACBC in Patients with Biochemical Recurrence of Prostate Cancer: A Retrospective Bicentric Study

Biomedicines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 177
Author(s):  
Luca Filippi ◽  
Oreste Bagni ◽  
Carmelo Crisafulli ◽  
Ivan Cerio ◽  
Gabriele Brunotti ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Management ◽  
Biochemical Recurrence ◽  
Detection Rate ◽  
Major Change ◽  
Emission Computed Tomography ◽  
Prostate Bed ◽  
Pet Ct ◽  
Significant Difference ◽  
Clinical Records

Our aim was to assess the detection rate (DR) of positron emission computed tomography (PET/CT) with anti-1-amino-3-[18F]-flurocyclobutane-1-carboxylic acid (18F-FACBC) in patients with biochemical recurrence (BCR) from prostate cancer (PC). As a secondary endpoint, we evaluated 18F-FACBC PET/CT’s impact on patients management. Clinical records of 81 patients submitted to 18F-FACBC PET/CT due to PC BCR in two Italian Nuclear Medicine Units were retrospectively assessed. DR was gauged in the whole cohort and stratifying patients by discrete intervals of PSA levels. PET/CT’s impact on clinical management was scored as (1) major if it entailed an intermodality change (e.g., from systemic to loco-regional therapy); (2) minor if it led to an intramodality change (e.g., modified radiotherapy field). PET/CT’s DR resulted in 76.9% in the whole cohort, with a positive predictive value of 96.7%. Stratified by PSA quartile intervals, PET/CT’s DR was 66.7%, 71.4%, 78.9% and 90% for PSA 0.2–0.57 ng/mL, 0.58–0.99 ng/mL, 1–1.5 ng/mL and >1.5 ng/mL without significant difference among groups (p = 0.81). The most common sites of relapse were prostate bed and pelvic lymph nodes (59.3%). PET/CT impacted on clinical management in 33/81 cases (40.7%), leading to a major change in 30 subjects (90.9%). 18F-FACBC PET/CT localized recurrence in patients with BCR, with meaningful DR also at low PSA levels and significantly impacted on clinical management.

scholarly journals Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Jiale Sun ◽  
Yuxin Lin ◽  
Xuedong Wei ◽  
Jun Ouyang ◽  
Yuhua Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Early Detection ◽  
Publication Bias ◽  
Detection Rate ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Recurrent Prostate Cancer ◽  
Pet Ct ◽  
Statistical Heterogeneity

Background: Prostate-specific membrane antigen (PSMA)-targeted 2-(3-{1-carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) positron emission tomography/computed tomography (PET/CT) has shown advantages in primary staging, restaging, and metastasis detection of prostate cancer (PCa). However, little is known about the role of 18F-DCFPyL PET/CT in biochemically recurrent prostate cancer (BRPCa). Hence, we performed a systematic review and meta-analysis to evaluate 18F-DCFPyL PET/CT as first-line imaging modality in early detection of BRPCa.Methods: A comprehensive literature search of PubMed, Web of Science, Embase, and Cochrane Library was conducted until December 2020. The pooled detection rate on a per-person basis and together with 95% confidence interval (CI) was calculated. Furthermore, a prostate-specific antigen (PSA)-stratified performance of detection positivity was obtained to assess the sensitivity of 18F-DCFPyL PET/CT in BRPCa with different PSA levels.Results: A total of nine eligible studies (844 patients) were included in this meta-analysis. The pooled detection rate (DR) of 18F-DCFPyL PET/CT in BRPCa was 81% (95% CI: 76.9–85.1%). The pooled DR was 88.8% for PSA ≥ 0.5 ng/ml (95% CI: 86.2–91.3%) and 47.2% for PSA &lt; 0.5 ng/ml (95% CI: 32.6–61.8%). We also noticed that the regional lymph node was the most common site with local recurrence compared with other sites (45.8%, 95% CI: 42.1–49.6%). Statistical heterogeneity and publication bias were found.Conclusion: The results suggest that 18F-DCFPyL PET/CT has a relatively high detection rate in BRPCa. The results also indicate that imaging with 18F-DCFPyL may exhibit improved sensitivity in BRPCa with increased PSA levels. Considering the publication bias, further large-scale multicenter studies are warranted for validation.

scholarly journals [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients

2021 ◽  
Vol 93 (1) ◽  
pp. 21-25
Author(s):  
João Carvalho ◽  
Pedro Nunes ◽  
Edgar Tavares Da Silva ◽  
Rodolfo Silva ◽  
João Lima ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Complete Remission ◽  
Biochemical Recurrence ◽  
Detection Rate ◽  
Salvage Treatment ◽  
Clinical Approach ◽  
Curative Intent ◽  
Psma Pet ◽  
Pet Ct ◽  
Pelvic Relapse

Objectives: Clinical approach of prostate cancer (PCa) biochemical recurrence (BCR) is an ever-changing topic. Prostate-specific membrane antigen positron emission tomography ([68Ga]Ga-PSMA-11 PET-CTPSMA PET-CT) has shown good potential in this field. The aim is to evaluate PSMA PET-CT detection rate in PCa BCR and assess its impact on clinical outcome. Material and methods: Out of 319 patients with PCa who underwent PSMA PET-CT between October 2015 and June 2019, 70 had developed BCR after treatment with curative intent. Two groups were created: one with BCR after surgery (RP group) (N: 48; 68.6%) and other with BCR after radiotherapy (RT group) (N: 22; 31.4%). Clinical, analytical, pathological and PSMA PET-CT results were evaluated. Results: Initial age was different between groups (p = 0.008). RP patients were mainly at intermediate risk (85.1% vs 42.9%, p = 0.001) while RT patients were at low risk of recurrence (8.5% vs 47.6%, p = 0.001). In RP and RT groups, PSMA PETCT detected, respectively, pelvic relapse in 31.3% and 63.6%, and extrapelvic relapse in 18.8% and 31.8%. Salvage treatment was performed in 61.9% (n = 26) of RP patients and in 15% (n = 3) of RT patients, p < 0.001. Of RP patients submitted to salvage treatment, 59.1% achieved complete remission. Concerning these patients, local radiotherapy led to complete remission in 68.4% (n = 13). Of RT patients submitted to salvage treatment, two had complete remission and one had partial remission.Concerning detection rate, PSMA PET-CT was positive for pelvic relapse when pre-PET PSA ≥ 0.8 ng/mL (RP) or ≥ 2.3 ng/mL (RT) and for extrapelvic relapse when PSA ≥ 0.4 ng/mL (RP) or ≥ 3.5 ng/mL (RT), p > 0.05. Conclusions: Biochemical persistence rate after salvage therapy was similar (30-40%). The cut-off PSA values for pelvic relapse detected on PSMA PET-CT were ≥ 0.8 ng/mL (RP) and ≥ 2.3 ng/mL (RT).

Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer

2008 ◽  
Vol 113 (6) ◽  
pp. 895-904 ◽  
Author(s):  
E. Pelosi ◽  
V. Arena ◽  
A. Skanjeti ◽  
V. Pirro ◽  
A. Douroukas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Whole Body ◽  
Disease Detection ◽  
Biochemical Relapse ◽  
Radical Treatment ◽  
Choline Pet ◽  
Pet Ct

11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy

2012 ◽  
Vol 40 (2) ◽  
pp. 149-155 ◽  
Author(s):  
Francesco Ceci ◽  
Paolo Castellucci ◽  
Marcelo Mamede ◽  
Riccardo Schiavina ◽  
Domenico Rubello ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Biochemical Relapse ◽  
Choline Pet ◽  
Pet Ct ◽  
Hormone Resistant Prostate Cancer

Importance of Gleason score on 18F-choline PET/CT findings in patients with biochemical relapse of prostate cancer disease (PSA<1.0 ng/ml).

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 86-86 ◽  
Author(s):  
Marina Hodolic ◽  
Marino Cimitan ◽  
Jure Fettich
Keyword(s):  
Prostate Cancer ◽  
Gleason Score ◽  
Fdg Pet ◽  
Combined Treatment ◽  
Ct Imaging ◽  
Biochemical Relapse ◽  
Cancer Disease ◽  
Ct Findings ◽  
Pet Ct ◽  
Fdg Pet Ct

86 Background: Not all tumors show significant increase of metabolic activity on 18F-FDG PET/CT imaging. This is particularly true for prostate cancer, neuroendocrine tumors and hepatic tumors. As a component of cell membrane phospholipids, choline is an excellent biomarker for the malignant transformation and increased proliferation of cells. 18F-choline (18F-FCH) PET/CT is a nuclear medicine procedure that has greater sensitivity and accuracy than 18F-FDG PET/CT to detect prostate malignancy: sensitivity 73% vs. 31% and accuracy 67% vs. 53%, respectively. The efficiency of FCH to detect prostate cancer disease before and after treatment is related to the PSA levels. Evaluation of recurrent disease with 18F-FCH PET/CT imaging in patients with prostate cancer disease is becoming a routine procedure. Purpose: To investigate the role of Gleason score (GS), as a marker of proliferation, on 18F-FCH PET/CT findings in patients with biochemical relapse of prostate cancer disease defined as increased level of prostate specific antigen (PSA). Methods: 140 patients with biochemical relapse (PSA<1.0 ng/ml) underwent 18F-FCH PET/CT scan after treatment: radical prostatectomy, radiotherapy, hormonal therapy alone or combined treatment. Results: 18F-FCH PET/CT detected prostate cancer recurrence in 97% of patients with GS>7, 82% of patients with GS=7 and 63% of patients with GS<7. All patients had PSA between 0.2 and 1.0 ng/ml. Out of 140 patients 43% had recurrence in prostatic bed and 57% patients had local metastasis. Conclusions: Prostate cancer proliferation defined as Gleason score, influence 18F-FCH PET/CT findings in patients with biochemical relapse of prostate cancer disease at any PSA level.

Sign in / Sign up

Export Citation Format

Share Document